We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2),  influenza viruses, noroviruses and hepatitis C viruses.  We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat pandemic and seasonal influenza and the global COVID-19 health crisis. Given the growing global need for effective, safe antiviral treatments, we are advancing multiple antiviral therapeutic candidates as quickly and efficiently as possible, while also advancing the discovery and development of antiviral compounds for other high-value indications.

Targeted Solutions for Viral Diseases

Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

View Product Pipeline

About Us

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Learn More

Technology

We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Learn More

Development Programs

Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

Learn More
Program Discovery Preclinical Phase 1 Phase 2 Phase 3
Influenza A Oral PB2 Inhibitor CC-42344
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Influenza A Inhaled PB2 Inhibitor CC-42344
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase complete
Influenza A/B Replication Inhibitors
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Norovirus & Coronavirus Oral Pan-viral Protease Inhibitor CDI-988
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Coronavirus (Licensed) Protease Inhibitor CDI-45205
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Norovirus Replication Inhibitors
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Respiratory Viruses Pan-viral Inhibitors
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Investor Presentation

View our latest Corporate Presentation

View Presentation